PaRftZLfx方案在难治性肺结核中的应用效果评价  

Evaluation of the Application Effect of PaRftZLfx Regimen in Refractory Pulmonary Tuberculosis

作　　者：黄自强 朱晶 张设 吴俊杰 HUANG Ziqiang;ZHU Jing;ZHANG She;WU Junjie(Department of Lung Disease,Yangzhou Third People's Hospital,Yangzhou 225125,China)

机构地区：[1]扬州市第三人民医院肺病科,江苏扬州225125

出　　处：《中国医学创新》2025年第11期144-148,共5页Medical Innovation of China

基　　金：扬州市科技计划项目(YZ2021074)。

摘　　要：目的:探讨难治性肺结核治疗中选择PaRftZLfx治疗的价值。方法:选择80例难治性肺结核患者,病例均于2022年2月—2023年10月在扬州市第三人民医院肺病科就诊,依据随机数字表法分两组,对照组40例给予LfxEPAS化疗方案,观察组40例给予PaRftZLfx治疗,比较治疗3个月后临床疗效,治疗2、4、6个月后痰菌转阴率,治疗6个月后空洞闭合情况,3个月内不良反应发生率,治疗3个月后免疫功能变化。结果:观察组总有效率、痰菌转阴率、空洞闭合情况均优于对照组,差异均有统计学意义(P<0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。相比治疗前,两组治疗3个月后CD3+、CD4+、CD4+/CD8+均明显升高,CD8+均显著降低,观察组均优于对照组,差异均有统计学意义(P<0.05)。结论:难治性肺结核治疗中选择PaRftZLfx可改善空洞闭合情况、痰菌转阴率,亦可确保治疗有效性及安全性,提升免疫功能。Objective:To explore the value of PaRftZLfx regimen in the treatment of refractory pulmonary tuberculosis.Method:A total of 80 patients with refractory pulmonary tuberculosis were selected,all of whom were admitted to the Department of Lung Disease of Yangzhou Third People's Hospital from February 2022 to October 2023.They were randomly divided into two groups according to the random number method.The control group(40 cases)received LfxEPAS chemotherapy regimen,while the observation group(40 cases)received PaRftZLfx treatment.The clinical efficacy after 3 months of treatment,sputum conversion rate after 2,4,and 6 months of treatment,cavity closure after 6 months of treatment,incidence of adverse reactions within 3 months,and changes in immune function after 3 months of treatment were compared.Result:The total effective rate,sputum conversion rate,and cavity closure in the observation group were all better than those in the control group,the differences were statistically significant(P<0.05).The incidence of adverse reactions in the observation group was lower than that in the control group,the difference was statistically significant(P<0.05).Compared with before treatment,CD3+,CD4+,CD4+/CD8+in both groups increased significantly after 3 months of treatment,while CD8+decreased significantly,the observation group were superior to the control group,the differences were statistically significant(P<0.05).Conclusion:Choosing PaRftZLfx in the treatment of refractory pulmonary tuberculosis can improve cavity closure,sputum conversion rate,ensure treatment effectiveness and safety,and enhance immune function.

关 键 词：利福喷丁 难治性肺结核 空洞闭合 痰菌转阴 

分 类 号：R521[医药卫生—内科学]